Form 13G 89bio For: 14 November
- Investing.com
Pegozafermin's Promise | Explore 89bio's lead candidate in Phase III trials for MASH and SHTG, potentially unlocking billion-dollar market opportunities in liver and cardio-metabolic diseases |
Market Dynamics | Delve into the evolving landscape of MASH treatments, including the impact of GLP-1 therapies and how pegozafermin aims to differentiate itself |
Financial Outlook | Analyst targets range from $12 to $49 per share, reflecting varied assumptions about pegozafermin's potential across multiple indications |
Strategic Positioning | Learn how 89bio's pipeline-in-a-product strategy and favorable regulatory environment could shape its future in the competitive biopharmaceutical space |
Metrics to compare | ETNB | Peers Peers - average of corresponding metrics from companies closely matching ETNB: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipETNBPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 54.3% | |
Fair Value Upside | Unlock | 0.0% | 7.2% | Unlock |